Phase I PKPD study of Lanifibranor in healthy volunteers
Latest Information Update: 24 Sep 2023
At a glance
- Drugs Lanifibranor (Primary)
- Indications Fibrosis; Liver cirrhosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 24 Sep 2023 New trial record